Stutsky explains why shifting therapy perceptions had more pharmacist touchpoints and longer time on therapy among patients with ATTR-CM.

The FDA approved remibrutinib (Rhapsido; Novartis) today, October 7, 2026, as the first treatment for adults with symptomatic ...

AJMC: Despite ATTR-CM being a progressive disease, 74% of patients reported no change in perception. Is that reassuring from ...

Fibrosis stage, not MASH resolution, best predicts mortality, which should shape trial end points, says Georgetown's Zobair Younossi, MD, MPH.

Risk assessment in mantle cell lymphoma (MCL) is evolving beyond traditional clinical scores, as genomic and dynamic ...

Bilbrey’s Tennessee Oncology colleage Johnetta Blakely, MD, MS, MMHC, who is also chief medical officer for COA, has ...

Michael Mina, MD, PhD, explains which adverse events drove VYD2311's edge vs an mRNA COVID-19 vaccine and who may benefit most. Invivyd's investigational monoclonal antibody VYD2311 showed superior ...

Survivors of childhood and young adult acute lymphoblastic leukemia (ALL) treated with modern regimens had lower hip bone mineral density (BMD) than matched controls, with the largest deficits among ...

Sacral neuromodulation (SNM) is still considered the gold standard neuromodulation option for refractory overactive bladder ...

"We believe retatrutide is a biologic application," Eli Lilly’s CEO Dave Ricks, MBA, told analysts on the company's second-quarter earnings call in August. The outcome will shape how long retatrutide ...

OneOncology's Edward "Ted" Arrowsmith, MD, MPH, explains how patient-reported outcomes and national disease groups can make cancer pathways more dynamic. 259 Prospect Plains Rd, Bldg H Cranbury, NJ 08 ...

Clinical pathways in oncology need to move beyond static documents and incorporate the patient's voice through real-time data ...